GSK shifts 2,200 posts for 'growth'
Marc Iskowitz
November 13 2009
Instead of merely slashing reps to trim costs, GlaxoSmithKline is relocating the positions, said CEO Andrew Witty.
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Your message:
The e-mail address(es) that you supply to use this service will only be used to send the requested article.